The per share price values Santarus at $2.6 billion, a 39 percent premium over the company’s 30-day trading average.
The acquisition will help Salix solidify its lead in the gastrointestinal market, and the companies’ combined revenue would be approximately $1.3 billion.
More Articles on Gastroenterology:
72% of Adults Have Not Sought Physician Help for GI Pain
Physicians Endoscopy Receives Cost Management Performance Award
Dr. Glenn Madokoro Gives GI Patients Access to Information Technology
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
